加载中
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
收盘时
US$2.02
−US$0.12 · -5.61%
盘后
US$2.06
+US$0.04 · +1.98%
10月12日 17:12 ET
盘中时间采用ET。市场数据可能有所延迟。
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
日内区间
当前US$2.02
52周区间
当前US$2.02
盘中时间采用ET。市场数据可能有所延迟。
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
日内区间
当前US$2.02
52周区间
当前US$2.02
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | — | — | 1230.5万 USD |
| 毛利 | — | — | — | — | −1230.5万 USD |
| 研究与开发 | 1.05亿 USD | 9379.8万 USD | 4231.8万 USD | 3236.1万 USD | 1230.5万 USD |
| 销售、一般及管理费用 | 1894.7万 USD | 2021.9万 USD | 1882万 USD | 1287.6万 USD | 727.9万 USD |
| 营业费用 | 1.24亿 USD | 1.14亿 USD | 6113.8万 USD | 4523.7万 USD | 727.9万 USD |
| 利息收入 | 744.7万 USD | 1431.7万 USD | 1079.1万 USD | 239.2万 USD | 8.4万 USD |
| 利息支出 | 422.4万 USD | 406.8万 USD | 58.1万 USD | — | — |
| 折旧和摊销 | 18.4万 USD | 17.8万 USD | 18.4万 USD | 16.9万 USD | 4000 USD |
| 营业利润 | −1.24亿 USD | −1.14亿 USD | −6113.8万 USD | −4523.7万 USD | −1958.4万 USD |
| 净利润 | −1.21亿 USD | −1.02亿 USD | −5237.1万 USD | −4285.6万 USD | −1.01亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$7.00
上涨空间 246.53%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI318.72万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM252.65万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF146.35万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO76.94万0.00%180亿 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC32.16万0.02%13.17亿 USD0.60%US$181.66-0.73%
Dimensional - US Small Cap ETFDFAS26.15万0.00%338.69亿 USD0.31%US$78.17-0.23%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM18万0.16%1.17亿 USD0.73%US$15.8484-0.58%
Vanguard Russell 2000 Value ETFVTWV12.48万0.01%14亿 USD0.06%US$185.97+0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
